Clinical Trials

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07353840 2026-01-20

T-START-CR

Recruiting

160 enrolled

Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

160 enrolled

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Recruiting

70 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

595 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

86 enrolled

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

264 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05350722 2024-12-30

ABLATIVE-2

100 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05000697 2024-11-27

CCHOWW

216 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

65 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT03125343 2023-11-07

WoW

400 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

145 enrolled

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT04743102 2023-02-21

BIOPSY

260 enrolled